Showing results (21-30 of 28) with videos related to
Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Interactive Cardiovascular and Thoracic Surgery|May 23, 2018
The flutter-by effect: a comprehensive study of the fluttering cusps of the Perceval heart valve prosthesisAli Aljalloud, Mohamed Shoaib, Sandrine Egron, et al.Cancer Medicine|November 19, 2019
Are population-based patient-reported outcomes associated with overall survival in patients with advanced pancreatic cancer?Wei Fang Dai, Jaclyn Beca, Helen Guo, et al.JAMA Network Open|November 15, 2021
The Association of Drug-Funding Reimbursement With Survival Outcomes and Use of New Systemic Therapies Among Patients With Advanced Pancreatic CancerMichael J Raphael, William Raskin, Steven Habbous, et al.Leukemia & Lymphoma|December 6, 2018
Improved survival in overweight and obese patients with aggressive B-cell lymphoma treated with rituximab-containing chemotherapy for curative intentJames K R Stevenson, Yao Qiao, Kelvin K W Chan, et al.JNCI Cancer Spectrum|June 27, 2022
Real-World Cost-Effectiveness of First-Line Gemcitabine Plus Nab-Paclitaxel vs FOLFIRINOX in Patients With Advanced Pancreatic CancerVanessa Arciero, Jin Luo, Ambica Parmar, et al.Cancer Medicine|November 15, 2019
Real-world outcomes of FOLFIRINOX vs gemcitabine and nab-paclitaxel in advanced pancreatic cancer: A population-based propensity score-weighted analysisKelvin K W Chan, Helen Guo, Sierra Cheng, et al.JAMA Network Open|August 2, 2022
Comparison of Use of Neoadjuvant Systemic Treatment for Breast Cancer and Short-term Outcomes Before vs During the COVID-19 Era in Ontario, CanadaSteven Habbous, Xiaochen Tai, Jaclyn M Beca, et al.Current Oncology (Toronto, Ont.)|October 22, 2021
Considerations for Developing a Reassessment Process: Report from the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration's Reassessment and Uptake Working GroupWei Fang Dai, Vanessa Arciero, Erica Craig, et al.Pageof 3